We found that blocking IL-2 (and IL-2 + IL-12) significantly reduced the frequency of Th cells expressing GM-CSF but not co-expressing IFN-γ or IL-17 (called Th-GM) in PBMC from MS patients but not in HCs (blocking IL-2: MS n = 9, Wilcoxon test p = 0.0039; HC n = 10, Wilcoxon test p > 0.99; Figure 7A,B). The gene discussed is CSF2; the disease is myeloid sarcoma.